Fundraising FoxHoxton Ventures — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Formance provides a platform for developers to build and integrate complex financial applications using composable, open-source primitives that can connect to any financial partner.
Data & InfrastructureDeveloper ToolsEnterprise SoftwareFintechSaaSParis, FR
Clément Salaün(Founder)inAnne-Sybille Pradelles(Founder)inMaxence Maireaux(Vice President Engineering)Taylor Martin(Project Manager)Clio Murphy(Project Manager)Maylis Pichon(Project Manager)
Co-investorsAxeleo CapitalPortage VenturesY CombinatorFAST — by GETTYLABFrstKima Ventures+4 more
Milvus Advanced is a deeptech company that designs and manufactures high-performance nanomaterials and nanoalloys from abundant raw materials as replacements for scarce materials such as platinum-group metals.
Advanced ManufacturingCleantechDeep TechNew MaterialsOxford, GB
Assia Kasdi(Founder)in
Co-investorsLowercarbon CapitalÜbermorgen VenturesUnruly CapitalAcequia Capital OriginEQT VenturesMD One Ventures+3 more
PentaBind designs programmable aptamers—small RNA/DNA molecules with sub-nanomolar binding affinity—for continuous sensing and diagnostics applications (e.g., monitoring hormones and biomarkers) and targeted therapeutics in oncology and drug delivery.
BiotechDeep TechMedical DevicesLondon, GB
Rory Ryan(CEO & Co-founder)inPhil Haynes(CTO & Co-founder)inMiguel Gonzalez Canudas(Founder)inDr. Miguel Gonzalez(CAIO & Co-founder)
Co-investorsEntrepreneur FirstTwin Path Ventures
Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Arne Scheu(Founder)inIrsyad Khairil(Founder)in
Co-investorsLongeVCMetaplanetOxonian VenturesP53 InvestRV Invest GmbHSynBioVen+9 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.